The incidence of cerebral and extracerebral toxoplasmosis among 1,699 HIV-infected patients followed in the SEROCO and HEMOCO cohorts (1988 -1995) 
Assessment of risk factors for opportunistic infections in
antibody titer of §150 IU/mL was found to be predictive of toxoplasmic encephalitis [7] . The delay between the antibody HIV-infected patients helps to establish the indications for and type of specific prophylaxis. The CD4 cell count is an index increase and the onset of toxoplasmosis remains to be determined and might be an important factor concerning the start of immunodeficiency, and the risk of opportunistic infection increases markedly when values fall below 200/mL [1] . The of prophylaxis. In this study we examined the serological and clinical feaspecific risk of toxoplasmosis is also estimated on the basis of the patient's specific serological status: the presence of Toxtures of cases of toxoplasmosis occurring among 1,699 HIVinfected patients followed between 1988 and 1995 in the French oplasma antibodies indicates latent infection that may reactivate as the immunodeficiency progresses [2] . Patients who are HEMOCO and SEROCO cohorts, before the era of protease inhibitors. We also studied the incidence of seroconversion and seronegative for Toxoplasma are considered to be at a lower risk for developing toxoplasmic encephalitis, but there are few serological reactivation in the course of HIV infection and estimated their predictive value for toxoplasmosis. data on the incidence of primary infections and the risk of severe toxoplasmosis (cerebral or extracerebral) for these patients [3 -5] .
Patients and Methods It is recommended that serological testing for Toxoplasma be done soon after the diagnosis of HIV infection [6] ; the
Study Population and Follow-Up presence of antibodies reflects latent infection with Toxoplasma
The study population consisted of 1,699 patients followed gondii. High titers of IgG to Toxoplasma or an increase in the between 1988 and 1995 in two multicenter French cohorts used specific IgG titer is more frequent in HIV-infected patients to study the natural history of HIV infection in hemophiliacs who develop toxoplasmic encephalitis than in other patients (HEMOCO cohort) [12] and nonhemophiliac adults (SEROCO [7 -11] . In patients with CD4 cell counts below 200/mL, an cohort) [13, 14] . In both cohorts the patients were volunteers, and HIV infection was defined by a positive ELISA and confirmatory western blot. In the SEROCO cohort the patients were enrolled no more than 1 year after the diagnosis of HIV Table 1 . Characteristics of HIV-infected patients included in the started (with cotrimoxazole, pyrimethamine plus dapsone, or SEROCO and HEMOCO cohorts (1988 -1995 estimate the 95% confidence interval (CI) of the incidence rates qualitatively (presence or absence). Seroconversion was diag- [17] . The relative risks (RRs) associated with the factors of nosed when a patient with a negative IgG serology subseprogression to toxoplasmosis were estimated by the fitting of quently had an IgG titer of §10 IU/mL in association with the a Cox model with fixed or time-dependent variables [18] . Difpresence of IgM. The proportion of specific antibodies in the ferent thresholds of positivity of IgG antibody titers (from 50 total pool of IgG, termed the Toxoplasma immune load [15, to 350 IU/mL, by 50-step progression) and immune load (from 16], was calculated as the ratio of Toxoplasma IgG antibody 25 to 175 IU/mg, by 25-step progression) were tested for their titer (IU/mL) to total serum level of IgG (mg/mL); results were predictive value on the occurrence of toxoplasmosis. The analyexpressed in IU/mg. ses were performed with use of SAS software (SAS Institute, Cary, NC).
Diagnosis of Cerebral and Extracerebral Toxoplasmosis
Cases of toxoplasmosis were reported by each center at the Results time of diagnosis. The location (cerebral, pulmonary, ocular, or disseminated) was specified, together with the main diagnostic Between January 1988 and January 1996, 1,502 patients in criteria (clinical signs, including ophthalmologic findings; rathe SEROCO cohort (438 women and 1,064 men) and 197 diological signs on brain CT or MRI; demonstration of patients in the HEMOCO cohort were recruited. Their baseline T. gondii on stained smears or by mouse inoculation or tissue characteristics are shown in table 1. During follow-up (median culture; and response to specific therapy). For this study each duration, 60.5 months after inclusion, corresponding to 7,649 case was reexamined by a validation committee using medical py), 488 patients' conditions progressed to CDC (Centers for and laboratory files and was classified according to the degree Disease Control and Prevention) group C status, and 390 deaths of diagnostic reliability. Toxoplasmosis was considered (1) were recorded. definite if T. gondii was visualized or isolated from blood or any tissue, in addition to the finding of clinical and radiological
Cases of Toxoplasmosis
signs; (2) probable if clinical and radiological signs improved on specific treatment; and (3) possible when clinical and radioOne hundred sixteen patients developed definite, probable, logical manifestations improved but did not resolve with speor possible toxoplasmosis (table 2) . The cerebral location was cific therapy or when the diagnosis could not be confirmed largely predominant, occurring in 103 (88.8%) of the 116 cases; retrospectively (medical file not available).
other forms were pulmonary, ocular, and disseminated. The median CD4 cell count was 58/mL at the onset of toxoplasmo-
Statistical Analysis
sis. Eighteen (15.5%) of the patients had received specific prophylaxis before onset (cotrimoxazole, 11; clindamycin, 2; disuThe cutoff date for this analysis was 1 January 1996. Incidence rates were computed as the number of events per 100 lone, 1; and pyrimethamine alone, 4). This proportion was / 9c63$$mr06 02-24-99 11:16:10 cida UC: CID the estimated incidence of toxoplasmosis among patients with CD4 cell counts of õ200/mL remained stable between 1988 (6.9/100 py) and 1992 (6.7/100 py). After 1992, the decreasing significantly lower than that of patients who did not develop incidence of toxoplasmosis was probably linked to the widetoxoplasmosis (30.5%; P õ .001).
spread use of prophylaxis. The Toxoplasma serology was positive in 113 patients (97.4%), with a median Toxoplasma IgG titer of 150 IU/mL at the time of diagnosis (first quartile Å 60; third quartile Å Titers of Antibody to Toxoplasma 240); none had detectable IgM antibodies at the time of diagnosis. Among these 113 patients, 78 (69.0%) had had an increase A total of 12,288 serological results were analyzed. At the time of their inclusion in the study, the Toxoplasma serological in the Toxoplasma IgG titer (to §150 IU/mL) before clinical onset, within a median of 25 months previously (range, 10 status was determined for 1,683 patients (data were missing for 16). Serology was negative for 468 patients (27.8%). The days to 74 months). Three patients remained seronegative at the onset of toxoplasmosis; the absence of specific antibodies remaining 1,215 had serological evidence of exposure to Toxoplasma, with a median specific IgG titer of 66 IU/mL and a was confirmed by a negative dye test and negative direct agglutination test on frozen sera. In two antibody-negative patients median immune load of 34.8 IU/mg. The antibody titers and immune load values had a log-normal distribution. with possible toxoplasmic encephalitis, the last serological tests were performed 2 and 5 months before the diagnosis, and no ELISA methods were increasingly used over the years, accounting for 39.6% of antibody titer determinations in 1988 further frozen sera were available. The third patient had probable ocular toxoplasmosis, and his serology remained negative and 91.4% in 1995. As the conversion factor between immunofluorescence and ELISA antibody titers is unclear [19] , subseafter diagnosis (in 11 months of follow-up). The CD4 cell counts of these three patients were 66/mL, 1/mL, and 150/mL quent statistical analyses were based only on the subset of 903 patients tested exclusively with ELISA methods. Among these at diagnosis.
During the study period the overall incidence of toxoplasmopatients, 253 (28.0%) were seronegative at inclusion, and 14 seroconverted during follow-up, giving an incidence of 1.63 sis was estimated at 1.53/100 py (95% CI, 1.25 -1.81). The ; per 100 person-years), prevalence of toxoplasmosis prophylaxis (,, ,, ,, ; percentage of patients), and prevalence of CD4 cell counts õ200/mL (ᮀ; percentage of patients) among the SEROCO and HEMOCO cohorts, 1988 -1995. / 9c63$$mr06 02-24-99 11:16:10 cida UC: CID Table 3 . Risk factors for cerebral or extracerebral toxoplasmosis in the SEROCO and HEMOCO cohorts (1988 -1995) . by studying the risk of toxoplasmosis according to different thresholds in maximal values reached during follow-up. The IU/mL either at inclusion (n Å 187) or during follow-up; the incidence of increases in antibody to §150 IU/mL during folrisk of toxoplasmosis increased when the maximum antibody titer was §150 IU/mL or when the maximum immune load low-up can thus be estimated at 4.92/100 py (95% CI, 4.09 -5.75). The median CD4 cell count at the time of this increase was §50 IU/mg. The incidence of toxoplasmosis (table 4) was low among was 389/mL. The antibody increase occurred when the CD4 cell count was ú200/mL in 81.4% of cases.
seronegative patients (0.33/100 py). It remained low in Toxoplasma-seropositive patients with a CD4 cell count of §200/mL, although it increased to 0.53/100 py when the IgG
Risk Factors for Cerebral or Extracerebral Toxoplasmosis
antibody titer was §150 IU/mL. After the CD4 cell count had fallen below 200/mL, the incidence of toxoplasmosis increased Candidate risk factors for toxoplasmosis were the patients' significantly (to 3.45/100 py) among patients with antibody baseline characteristics and time-dependent factors such as an increase in the antibody titer to §150 IU/mL, a fall in the CD4 / cell count to õ200/mL, and the lack of specific prophy- marked in the multivariate analysis after adjustment for the CD4 cell count of õ200/mL and CD4 cell count (adjusted RR Å 0.18).
IgG titer of õ150 IU/mL 17/206 3.45 (1.95 -5.46) When the Toxoplasma antibody titer increased to ú150
IgG titer of §150 IU/mL 37/166 9.64 (6.88 -13.28) IU/mL (fitted as a time-dependent variable), patients were at a / 9c63$$mr06 02-24-99 11:16:10 cida UC: CID titers remaining below 150 IU/mL. It was even higher (9.64/ year for Toxoplasma antibodies. In the search for Toxoplasma antibodies, attention should be paid to the sensitivity of the 100 py) after the antibody titer increased to ú150 IU/mL. test used, in order to discriminate seropositivity from seronegativity, and to its reproducibility for determination of IgG antiDiscussion body titers. Several commercial ELISA kits fulfill these criteria, but the dye test or the sensitive agglutination test may also be This longitudinal analysis of clinical and serological data on 1,699 HIV-infected patients offered a unique opportunity to recommended for assessment of seropositivity in patients with low levels of antibodies. study the course of toxoplasma infection during HIV disease progression.
Seropositivity for Toxoplasma was associated with a much higher risk of toxoplasmosis. At the time of diagnosis, the Among these patients, 116 cases of cerebral or extracerebral toxoplasmosis were observed, given a mean incidence of median antibody titer was 150 IU/mL (with no detectable IgM antibodies). It has already been observed that the antibody 1.52/100 py. This high incidence of toxoplasmosis is not surprising, given the high prevalence (72.2%) of latent toxoplasma titer frequently increases before clinical onset [7 -11] . Using a threshold titer of 150 IU/mL, which was previously found to infection at enrollment, as in the general French population [5] . The incidence of toxoplasmosis varied with time, rising be indicative of a higher risk of toxoplasmic encephalitis in patients with low CD4 cell counts [7] , we found that 78 of the from 0.68/100 py in 1988 to 2.10/100 py in 1992, owing to the progression of HIV disease in the cohort and the limited 116 patients who developed toxoplasmosis had had such an increase in the IgG antibody titer, from 10 days to 74 months use of prophylaxis during this period. Incidence dramatically fell between 1992 and 1995, after the widespread introduction (median, 25 months) earlier. This interval was no doubt underestimated, as 59% of these patients already had such a level of specific prophylaxis.
As previously described [2] , toxoplasmosis was observed at of IgG antibodies at inclusion. A rise in the antibody titer to §150 IU/mL was associated with a higher risk of toxoplasmoan advanced stage of HIV disease, when the median CD4 cell count was only 58/mL. The cerebral location was the most sis (adjusted RR Å 3.53). The IgG value of §150 IU/mL was found to be the most predictive and discriminatory among those frequent (95% of cases). Eighteen patients had been prescribed prophylaxis for toxoplasma infection. Although compliance tested.
The increase in the Toxoplasma IgG titer is very likely to was not specifically assessed, such prophylactic failures could be attributed to irregular intake (explicitly recorded for five be specific for Toxoplasma and not due to a polyclonal increase in immunoglobulins. Indeed, by studying the anti-Toxoplasma patients who took cotrimoxazole). Poor efficacy of single-drug regimens (clindamycin [n Å 2], dapsone [n Å 1], or pyrimethimmune load, we found that a threshold of 50 IU/mg was predictive of toxoplasmosis. Israelski et al. [21] also observed amine [n Å 4]) might also explain some of these apparent failures.
frequent increases in the Toxoplasma antibody titers in HIVinfected patients, with no concomitant rise in total IgG or ruThe follow-up of Toxoplasma antibody titers allowed us to compare the incidence of toxoplasmosis among seronegative bella-specific IgG levels. Assuming that this response is specific, it could result either and seropositive patients and, in the latter group, to estimate the toxoplasmosis-predictive value of an increased antibody from reactivation of a chronic infection or from reinfection. This latter possibility cannot be ruled out, in view of occasional titer. For patients who were seronegative at entry, the incidence of seroconversion was 1.63/100 py (CI, 0.89 -2.73), in keeping reports of congenital toxoplasmosis following reinfection in seropositive pregnant women [22 -24] . In a recent study in with previously published values in France for HIV-infected patients (1% -2%) [4, 5] and pregnant women (2%) [20] and mice [25] , animals chronically infected with one strain could be reinfected by a different strain, with invasion of the brain for North American HIV-infected patients (2%) [3] . None of the 14 seroconversions were accompanied by severe clinical by the reinfecting strain. If reinfection can occur in humans, however, it is unlikely to explain all the antibody increases, manifestations, suggesting that the risk of severe toxoplasmosis immediately following primary toxoplasma infection is low in which occurred at a much higher rate than seroconversions. Several lines of evidence favor reactivation of chronic infec-HIV-infected patients. However, three cases of ocular or cerebral toxoplasmosis were documented, involving patients who tion. Experimental models have clearly shown the role of cellmediated immunity and cytokines in the containment of chronic remained persistently seronegative for both IgG and IgM antibodies. The possibility that a primary acquired infection failed toxoplasmosis [26] . These functions are profoundly altered in advanced HIV infection. In our patients, most of the antibody to elicit an antibody response because of the patients' profound immunodeficiency cannot be ruled out.
titer increases occurred a long time before clinical onset (median, 25 months), and the median CD4 cell count at the time For these reasons, behavioral recommendations to prevent T. gondii contamination are warranted for Toxoplasma-seroof the antibody increase was 389/mL. This suggests that rupture of dormant cysts, which probably underlies these serological negative patients with low CD4 cell counts [6] . In countries where the incidence of toxoplasmosis is high, seronegative reactivations, is not closely related to the CD4 cell count but rather to a functional immune defect such as an impaired blastopatients with low CD4 cell counts should be examined once a / 9c63$$mr06 02-24-99 11:16:10 cida UC: CID A potential limitation of our study is the fact that 48 of the 48 cases; similar relative risks were found, although confidence intervals could contain ''1'' due to the smaller sample size (data not shown).
